Johannes Karges develops anti-cancer agents that work in a targeted manner, rather than adversely affecting the entire body.
Q&A: How argenx’s CEO plans to create a sequel to Vyvgart (and beat the IRA)
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS